Log in

Crispr Therapeutics Stock Price, News & Analysis (NASDAQ:CRSP)

$39.00
-1.05 (-2.62 %)
(As of 10/23/2019 04:03 AM ET)
Today's Range
$38.31
Now: $39.00
$41.35
50-Day Range
$35.64
MA: $42.69
$49.57
52-Week Range
$22.22
Now: $39.00
$53.90
Volume568,099 shs
Average Volume607,389 shs
Market Capitalization$2.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.11
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRSP
CUSIPN/A
Phone41-41-561-3277

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.12 million
Book Value$7.56 per share

Profitability

Net Income$-164,980,000.00
Net Margins-15,136.56%

Miscellaneous

Employees188
Market Cap$2.13 billion
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.


Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

What is Crispr Therapeutics' stock symbol?

Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

How were Crispr Therapeutics' earnings last quarter?

Crispr Therapeutics AG (NASDAQ:CRSP) released its earnings results on Monday, July, 29th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.84. The company earned $0.32 million during the quarter, compared to analyst estimates of $47.57 million. Crispr Therapeutics had a negative net margin of 15,136.56% and a negative return on equity of 51.49%. The company's revenue for the quarter was down 70.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.82) EPS. View Crispr Therapeutics' Earnings History.

When is Crispr Therapeutics' next earnings date?

Crispr Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Crispr Therapeutics.

What price target have analysts set for CRSP?

13 brokerages have issued 1-year target prices for Crispr Therapeutics' shares. Their predictions range from $21.00 to $72.50. On average, they anticipate Crispr Therapeutics' stock price to reach $57.50 in the next twelve months. This suggests a possible upside of 47.4% from the stock's current price. View Analyst Price Targets for Crispr Therapeutics.

What is the consensus analysts' recommendation for Crispr Therapeutics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crispr Therapeutics.

What are Wall Street analysts saying about Crispr Therapeutics stock?

Here are some recent quotes from research analysts about Crispr Therapeutics stock:
  • 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (9/30/2019)
  • 2. Needham & Company LLC analysts commented, "Crispr reported 1Q19 financial results yesterday and we spoke w/ mgmt for an update. The company announced last night that regulatory agencies in both the U.S. and Canada have cleared initiation of a Phase 1/2 trial of CTX-110, an allogeneic CAR-T cell therapy in development for CD-19 cancers. Mgmt reiterated guidance for trial initiation in 2Q19. 1/2 trials of CTX-001 continue to enroll pts, although infusion of first pt in latter trial is not expected until mid-2019. Mgmt still aspires to present data from the CTX-001 program at the ASH mtg in Dec 2019, depending on trial progress. Reiterate BUY. Progression of CRISPR-based allogeneic CAR-T program into the clinic later in 2Q19 represents important milestone for the company." (5/1/2019)
  • 3. William Blair analysts commented, "CRISPR Therapeutics AG We are initiating coverage on CRISPR Perform rating and $39 fair value estimate. While we acknowledge the innovative nature of the CRISPR/Cas9 discovery and the ease of use and flexibility of the platform as a potential ex vivo and in vivo therapeutic modality, we view the most-progressed indications being targeted—beta-thalassemia and sickle cell with CTX001 in col- laboration with Vertex and allogeneic T-cell therapy for hematological malignancies (acute lymphocytic leukemia [ALL], non-Hodgkin lymphoma [NHL], and multiple myeloma [MM])—as hyper-competitive spaces where the company is behind the leaders in clinical development." (3/13/2019)

Has Crispr Therapeutics been receiving favorable news coverage?

Media headlines about CRSP stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Crispr Therapeutics earned a news impact score of -2.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Crispr Therapeutics.

Are investors shorting Crispr Therapeutics?

Crispr Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 4,880,000 shares, an increase of 5.4% from the August 30th total of 4,630,000 shares. Based on an average daily trading volume, of 490,200 shares, the days-to-cover ratio is currently 10.0 days. Currently, 16.9% of the company's stock are short sold. View Crispr Therapeutics' Current Options Chain.

Who are some of Crispr Therapeutics' key competitors?

What other stocks do shareholders of Crispr Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crispr Therapeutics investors own include Editas Medicine (EDIT), Micron Technology (MU), NVIDIA (NVDA), Intellia Therapeutics (NTLA), Alibaba Group (BABA), Canopy Growth (CGC), Shopify (SHOP), Netflix (NFLX), Advanced Micro Devices (AMD) and Sangamo Therapeutics (SGMO).

Who are Crispr Therapeutics' key executives?

Crispr Therapeutics' management team includes the folowing people:
  • Dr. Rodger Novak, Founder, Chairman & Pres (Age 52)
  • Dr. Samarth Kulkarni, CEO & Director (Age 40)
  • Mr. Michael John Tomsicek, Chief Financial Officer (Age 53)
  • Dr. Tony W. Ho, Head of R&D and Exec. VP
  • Dr. N. Anthony Coles Jr., Sr. Advisor (Age 59)

When did Crispr Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are Crispr Therapeutics' major shareholders?

Crispr Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Versant Venture Management LLC (7.75%), Essex Investment Management Co. LLC (0.14%), Ipswich Investment Management Co. Inc. (0.08%), Capital Investment Advisory Services LLC (0.04%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Flagship Harbor Advisors LLC (0.00%). Company insiders that own Crispr Therapeutics stock include Aktiengesellschaft Bayer, Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Tyler Dylan-Hyde, Versant Venture Capital V, LP and Vertex Pharmaceuticals (Europe. View Institutional Ownership Trends for Crispr Therapeutics.

Which institutional investors are selling Crispr Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, Essex Investment Management Co. LLC, Capital Investment Advisory Services LLC, Flagship Harbor Advisors LLC and Ipswich Investment Management Co. Inc.. Company insiders that have sold Crispr Therapeutics company stock in the last year include Kurt Von Emster, Lawrence Otto Klein, Rodger Novak and Samarth Kulkarni. View Insider Buying and Selling for Crispr Therapeutics.

Which institutional investors are buying Crispr Therapeutics stock?

CRSP stock was acquired by a variety of institutional investors in the last quarter, including Coastal Investment Advisors Inc., NEXT Financial Group Inc and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Crispr Therapeutics stock in the last two years include Aktiengesellschaft Bayer and Vertex Pharmaceuticals (Europe. View Insider Buying and Selling for Crispr Therapeutics.

How do I buy shares of Crispr Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Crispr Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $39.00.

How big of a company is Crispr Therapeutics?

Crispr Therapeutics has a market capitalization of $2.13 billion and generates $3.12 million in revenue each year. The company earns $-164,980,000.00 in net income (profit) each year or ($3.44) on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe.View Additional Information About Crispr Therapeutics.

What is Crispr Therapeutics' official website?

The official website for Crispr Therapeutics is http://www.crisprtx.com/.

How can I contact Crispr Therapeutics?

Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]


MarketBeat Community Rating for Crispr Therapeutics (NASDAQ CRSP)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  273 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  538
MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Featured Article: How Do Mutual Funds Work?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel